Unaudited Financial Results for the Quarter ended 30th June, 2026.

ANUH PHARMA LTD. CIN: L24230MH1960PLC011586 Regd. Office: 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai -40~018 Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com;Website:www.anuhpharma.com UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2026 (Rs. in Lakhs) 3 months 3 months 3 months 12 months ended ended ended ended Sr. 30/06/2026 31/03/2026 30/06/2025 31/03/2026 Particulars Audited Unaudited (Refer Note Unaudited Audited No.5) (1) (2) (3) (4) (5) (6) I Revenue from operations 19,381.04 20,211.72 18,647.94 77,165.74 II Other income (Refer Note No-6) 307.67 (125.46) 338.84 435.56 Ill Total Revenue (I + II) 19,688.71 20,086.26 18,986.78 77,601.30 IV Expenses: Cost of materials consumed 15,996.42 14,071.39 12,390.50 51,044.32 Purchases of Stock-in-Trade 414.33 282.87 2,649.64 7,919.67 Changes in inventories of finished goods, work-in- (1,579.88) 768.33 222.26 1,002.09 I oroqress and Stock-in-Trade Employee benefits expense 735.16 634.93 629.79 2,630.33 Finance costs 0.35 10.58 21.13 47.23 Depreciation and amortization expense 243.28 300.29 251.50 1,138.22 Other expenses 2,1 86.24 2,465.92 1,726.65 8,397.30 Total expenses (IV) 17,995.90 18,534.31 17,891.47 72,179.16 v Profit I (Loss) before exceptional and Items and 1,692.81 1,551.95 1,095.31 5,422.14 tax (Ill -IV) VI Exceptional items - - - - VII Profit I (Loss) before tax (V -VI) 1,692.81 1,551.95 1,095.31 5,422.14 VIII Tax expenses: (1) Current tax 413.20 496.10 249.00 1,518.10 (2) Deferred tax 137.12 (91.73) 16.19 (184.39) (3) Income tax of earlier years - (20.56) - (16.18) Total Tax expenses (VIII) 550.32 383.81 265.19 1,317.53 IX Profit/(Loss) after Tax (VII-VIII) 1,142.49 1,168.14 830.12 4,104.61 x Other Comprehensive Income (i) items that will not be reclassified to profit or loss (4.40) (39.22) (8.11) 24.73 (ii) Income Tax relating to the items that will not be 1.11 9.88 2.04 (6.22) reclassified to profit or loss (ii) Items that will be reclassified to profit or loss - - Total Other Comprehensive Income (3.29) (29.34) (6.07) 18.51 (net of Tax) (Xl (net of Tax) Total Comprehensive Income for the period (IX XI + X) (Comprising Profit I (Loss) and Other 1,139.20 1,138.80 824.05 4,123.12 Comprehensive Income for the period) Paid up Equity Share Capital (Face value Rs. 5/-each) (Refer note no. 5,011.20 5,011.20 2,505.60 5,011.20 Other Equity - - - 30,211.04 (excluding revaluation reserves) Earnings per equity share XII (For respective periods) (In Rs.) (Refer note no. 4) (1) Basic 1.14 1.17 0.83 4.10 (2) Diluted 1.14 1.17 0.83 4.10 See accompanying notes to the financial results Notes:- 1. These unaudited financial results have been prepared in accordance with the recognition and measurement principles laid down in accordance with the Indian Accounting Standard (Ind AS) 34, "Interim Financial Reporting" as prescribed under Section 133 of the Companies Act 2013 ('the Act) read with the Companies (Indian Accounting Standards) Rules 2015, as amended from time to time, and other accounting principles generally accepted in India and in terms of Regulation 33 of the Securities Exchange Board ofindia ("SEBI'') (Listing Obligations and Disclosure Requirements) Regulations 2015 (as amended). 2. These unaudited financial results for the quarter ended 30th June, 2026 were reviewed by the Audit Committee and approved by the Board of Directors at its respective meeting held on 07th August, 2026 in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and have been subjected to limited review by the Statutory Auditors of the Company. 3. Other Financial indicators (Rs. in Lakhs) 3 months 3 months 3 months 12 months Particulars ended ended ended ended 30/06/2026 31/03/2026 30/06/2025 31/03/2026 Audited (Refer Unaudited Unaudited Audited Note No.5) EBITDA 1,936.44 1,862.82 1,367.94 6,607.59 % ofEBITDA Margin 9.99 9.22 7.34 8.56 EBITDA 1,814.45 2,356.40 1,008.64 6,784.24 (Adjusted to FOREX Gain I Loss and Other Income) % of Adjusted EBITDA Margin 9.36 11.66 5.41 8.79 4. During the quarter ended September 30, 2025 the shareholders of the company have approved, through the postal ballot, the issuance of the bonus shares, in the proportion of 1: 1 i.e. 1( one) bonus equity share of Rs 5 each for every 1( one) fully paid up equity share held on as on the record date. Accordingly, the company has allotted 5,01,12,000 as a bonus shares on 16th July, 2025 by utilization of General reserves. All the shares and per share information in the financial results reflect the effect of the bonus share issuance. 5. The figures of the quarter ended 31st March, 2026 are the balancing figures between the audited figures in respect of the full financial year upto 31st March, 2026 and the unaudited published year to date figures upto 3 lst December, 2025 being the date of end of the third quarter of financial year respectively which were subject to limited review. 6. Other income for the quarter ended 31st March 2026 includes mark to market loss on investment of~ .189.7 7 Lakhs. 7. The Company does not have any subsidiary/associate/joint ventures as on 30th June 2026. 8. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided. 9. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period. For Anuh Pharma Ltd. Ritesh Shah Place : Mumbai Joint Managing Director Date : 07th August, 2026 (DIN: 02496729) 111 (A) MAHATMA GANDHI ROAD, JAYANTILAL THAKKAR & CO. FORT, MUMBAI -400 023. CHARTERED ACCOUNTANTS Telephones: (91-22) 2265 8800 (91-22) 2265 ~900 E-Mails jtco23@jtco.co.in office@jtco.co.in Website : www.jtco.co.in Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of Anuh Pharma Limited (the "Company") Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended TO THE BOARD OF DIRECTORS Anuh Pharma Limited 1. We have reviewed the accompanying statement of unaudited financial results of Anuh Pharma Limited (the "Company'') for the quarter ended 30th June, 2026 (the "Statement'') attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations"). 2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assura [Showing first 8,000 characters — download PDF for full document]